The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells
Open accessAbstract
Bortezomib, a proteasome inhibitor, shows substantial anti-tumor activity in a variety of tumor cell lines, is in phase I, II, and III clinical trials and has recently been approved for the treatment of patients with multiple myeloma. The sequence of events leading to apoptosis following proteasome inhibition by bortezomib is unclear. Bortezomib effects on components of the mitochondrial apoptotic pathway were examined: generation of reactive oxygen species (ROS), alteration in the mitochondrial membrane potential (Delta psi m), and release of cytochrome c from mitochondria. With human H460 lung cancer cells, bortezomib exposure at 0.1 microM showed induction of apoptotic cell death starting at 24 h, with increasing effects after 48-72 h of treatment. After 3-6 h, an elevation in ROS generation, an increase in Delta psi m, and the release of cytochrome c into the cytosol, were observed in a time-dependent manner. Co-incubation with rotenone and antimycin A, inhibitors of mitochondrial electron transport chain complexes I and III, or with cyclosporine A, an inhibitor of mitochondrial permeability transition pore, resulted in inhibition of bortezomib-induced ROS generation, increase in Delta psi m, and cytochrome c release. Tiron, an antioxidant agent, blocked the bortezomib-induced ROS production, Delta psi m increase, and cytochrome c release. Tiron treatment also protected against the bortezomib-induced PARP protein cleavage and cell death. Benzyloxycarbonyl-VAD-fluoromethyl ketone, an inhibitor of pan-caspase, did not alter the bortezomib-induced ROS generation and increase in Delta psi m, although it prevented bortezomib-induced poly(ADP-ribose) polymerase cleavage and apoptotic death. In PC-3 prostate carcinoma cells (with overexpression of Bcl-2), a reduction of bortezomib-induced ROS generation, Delta psi m increase was correlated with cellular resistance to bortezomib and the attenuation of drug-induced apoptosis. The transient transfection of wild type p53 in p53 null H358 cells caused stimulation of the bortezomib-induced apoptosis but failed to enhance ROS generation and Delta psi m increase. Thus ROS generation plays a critical role in the initiation of the bortezomib-induced apoptotic cascade by mediation of the disruption of Delta psi m and the release of cytochrome c from mitochondria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Green, D. R., & Reed, J. C. (1998) · Science · doi:10.1126/science.281.5381.1309 · Cited by 8,965
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Hengartner, M. O. (2000) · Nature · doi:10.1038/35037710 · Cited by 5,779
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Mitochondrial control of cell death
Kroemer, G., & Reed, J. C. (2000) · Nature Medicine · doi:10.1038/74994 · Cited by 3,103
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Mitochondria as the central control point of apoptosis
Desagher, S., & Martinou, J.-C. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01803-1 · Cited by 1,913
Vaux, D. L., & Korsmeyer, S. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80564-4 · Cited by 1,570
Cited by
Oxyl radicals, redox-sensitive signalling cascades and antioxidants
Genestra, M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.04.009 · Cited by 4,930
Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Øvervatn, A., Stenmark, H., & Johansen, T. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200507002 · Cited by 3,276
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
ROS stress in cancer cells and therapeutic implications
Pelicano, H., Carney, D., & Huang, P. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2004.01.004 · Cited by 2,006
Oxidative cell death in cancer: mechanisms and therapeutic opportunities
An, X., Yu, W., Liu, J., Tang, D., Yang, L., & Chen, X. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-06939-5 · Cited by 523
Pérez-Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2006) · Blood · doi:10.1182/blood-2005-05-2091 · Cited by 467
Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., Scheffer, G. L., Debipersad, K., Vojtekova, K., Lemos, C., et al. (2008) · Blood · doi:10.1182/blood-2007-08-104950 · Cited by 454
Imbalanced GSH/ROS and sequential cell death
Liu, T., Sun, L., Zhang, Y., Wang, Y., & Zheng, J. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22942 · Cited by 453
Mulligan, G., Mitsiades, C., Bryant, B., Zhan, F., Chng, W. J., Roels, S., Koenig, E., Fergus, A., Huang, Y., Richardson, P., et al. (2007) · Blood · doi:10.1182/blood-2006-09-044974 · Cited by 416
Anticancer activity of Ficus religiosa engineered copper oxide nanoparticles
Sankar, R., Maheswari, R., Karthik, S., Shivashangari, K. S., & Ravikumar, V. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.08.030 · Cited by 411
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Jung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2
Liang, J., Cao, R., Wang, X., Zhang, Y., Wang, P., Gao, H., Li, C., Yang, F., Zeng, R., Wei, P., et al. (2017) · Cell Research · doi:10.1038/cr.2016.159 · Cited by 350
Deubiquitinase inhibition as a cancer therapeutic strategy
D'Arcy, P., Wang, X., & Linder, S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.002 · Cited by 310
Mechanisms of proteasome inhibitor action and resistance in cancer
McConkey, D. J., & Zhu, K. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.08.002 · Cited by 309
Golden, E. B., Lam, P. Y., Kardosh, A., Gaffney, K. J., Cadenas, E., Louie, S. G., Petasis, N. A., Chen, T. C., & Schönthal, A. H. (2009) · Blood · doi:10.1182/blood-2008-07-171389 · Cited by 289
N-acetylcysteine, reactive oxygen species and beyond
Sun, S.-Y. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.2.10583 · Cited by 288
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
Zheng, H., Xiao, W. H., & Bennett, G. J. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.08.016 · Cited by 272
Reactive oxygen species: Current knowledge and applications in cancer research and therapeutic
Lau, A. T. Y., Wang, Y., & Chiu, J. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21655 · Cited by 271
Vriend, J., & Reiter, R. J. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.12.013 · Cited by 246
Maharjan, S., Oku, M., Tsuda, M., Hoseki, J., & Sakai, Y. (2014) · Scientific Reports · doi:10.1038/srep05896 · Cited by 212
Butein induces G2/M phase arrest and apoptosis in human hepatoma cancer cells through ROS generation
Moon, D.-O., Kim, M.-O., Choi, Y. H., Hyun, J. W., Chang, W. Y., & Kim, G.-Y. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.07.002 · Cited by 151
Finn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Failure of protein quality control in amyotrophic lateral sclerosis
Kabashi, E., & Durham, H. D. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.06.006 · Cited by 90
Lu, J., Guo, J.-H., Tu, X.-L., Zhang, C., Zhao, M., Zhang, Q.-W., & Gao, F.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159998 · Cited by 79
Yadav, N., Dwivedi, A., Mujtaba, S. F., Verma, A., Chaturvedi, R., Ray, R. S., & Singh, G. (2014) · Cell Biology and Toxicology · doi:10.1007/s10565-014-9280-7 · Cited by 26
Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood · doi:10.1182/blood.2020010572 · Cited by 20
Metadata
- Authors
- Ling, Y.-H., Liebes, L., Zou, Y., & Perez-Soler, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 278
- Issue
- 36
- Pages
- 33714-33723
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084925682
- Cited by
- 458
- References
- 49
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.